Chikungunya Vaccine – Adverse Event Following Immunization (AEFI)                         

Key Messages:

  • CHIK‑LAV (IXCHIQ) is a single‑dose live attenuated chikungunya vaccine authorized for use in Canada; it is not publicly funded in Ontario and is available through private sale.
  • CATMAT advises the vaccine may be considered, following individualized risk assessment, for people aged 18–64 at high risk of infection, such as travellers to outbreak areas.
  • Serious adverse events following immunization (AEFI) have been reported in Canada, the U.S., and Europe, primarily among people aged 65+ and those with pre‑existing conditions.
  • Reported events include hospitalizations with chikungunya‑like illness and three deaths, including one directly attributable to the vaccine.
  • The U.S. FDA has suspended the vaccine’s license; CHIK‑LAV remains authorized in Canada and other jurisdictions.
  • Vaccine safety is being closely monitored, and health care providers are asked to report suspected AEFIs to their local public health unit using the standard reporting process.

More Information:

Ministry of Health Key Messages (PDF)